InvestorsHub Logo
Post# of 252233
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: DewDiligence post# 155804

Friday, 01/25/2013 8:12:58 AM

Friday, January 25, 2013 8:12:58 AM

Post# of 252233
GILD’s ‘Quad Prime’ advances to phase-3

Although genisi disagrees), TAF is a crucially important compound for GILD insofar as it effectively extends the patent life of the Truvada franchise.

To be clear, the doubt I've raised is that TAF regimen (‘Quad Prime’) will differ from Viread regimen (Stribild) in safety/efficacy terms. No doubt it is a crucially important compound for GILD in its patent extension strategy. The question I've pointed to is important because if TAF proves to be superior to Viread, it would be easier for GILD to switch patients to the TAF regimen even before Viread goes generic and keep them after generic competition.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.